View Item 

Show simple item record

The quantitative validation of non-endoscopic disease activity indices in ulcerative colitis

dc.contributor.authorHiggins, Peter D.R.en_US
dc.contributor.authorLeung, J.en_US
dc.contributor.authorSchwartz, M.en_US
dc.contributor.authorMapili, Johnen_US
dc.contributor.authorWren, Patricia A.en_US
dc.contributor.authorZimmermann, Ellen M.en_US
dc.date.accessioned2010-06-01T21:19:33Z
dc.date.available2010-06-01T21:19:33Z
dc.date.issued2007-02en_US
dc.identifier.citationHIGGINS, P. D. R.; LEUNG, J.; SCHWARTZ, M.; MAPILI, J.; WREN, P. A.; ZIMMERMANN, E. M. (2007). "The quantitative validation of non-endoscopic disease activity indices in ulcerative colitis." Alimentary Pharmacology & Therapeutics 25(3): 333-342. <http://hdl.handle.net/2027.42/74394>en_US
dc.identifier.issn0269-2813en_US
dc.identifier.issn1365-2036en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74394
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17269991&dopt=citationen_US
dc.format.extent659170 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights2007 The Authors Journal compilation 2007 Blackwell Publishing Ltden_US
dc.titleThe quantitative validation of non-endoscopic disease activity indices in ulcerative colitisen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum* Department of Internal Medicine, University of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationum¶ Department of Health Behavior and Health Education, University of Michigan, School of Public Health, Ann Arbor, MI, USAen_US
dc.contributor.affiliationother† Department of Internal Medicine, University of Iowa, Iowa;en_US
dc.contributor.affiliationother† Department of Internal Medicine, University of Chicago, Chicago;en_US
dc.contributor.affiliationother§ Department of Family Medicine, Wayne State University, Detroit;en_US
dc.identifier.pmid17269991en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74394/1/j.1365-2036.2006.03205.x.pdf
dc.identifier.doi10.1111/j.1365-2036.2006.03205.xen_US
dc.identifier.sourceAlimentary Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceTruelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 4947: 1041 – 8.en_US
dc.identifier.citedreferencePowell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978; 13: 833 – 7.en_US
dc.identifier.citedreferenceWalmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998; 43: 29 – 32.en_US
dc.identifier.citedreferenceLichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841 – 5.en_US
dc.identifier.citedreferenceSeo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992; 87: 971 – 6.en_US
dc.identifier.citedreferenceAzzolini F, Pagnini C, Camellini L, et al. Proposal of a new clinical index predictive of endoscopic severity in ulcerative colitis. Dig Dis Sci 2005; 50: 246 – 51.en_US
dc.identifier.citedreferenceSchroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625 – 9.en_US
dc.identifier.citedreferenceSutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92: 1894 – 8.en_US
dc.identifier.citedreferenceRutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462 – 76.en_US
dc.identifier.citedreferenceHiggins PD, Schwartz M, Mapili J, Krokos I, Leung J, Zimmermann EM. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005; 54: 782 – 8.en_US
dc.identifier.citedreferenceHiggins PD, Schwartz M, Mapili J, Zimmermann EM. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis ? Am J Gastroenterol 2005; 100: 355 – 61.en_US
dc.identifier.citedreferenceIrvine EJ. Quality of life – rationale and methods for developing a disease-specific instrument for inflammatory bowel disease. Scand J Gastroenterol Suppl 1993; 199: 22 – 7.en_US
dc.identifier.citedreferenceGuyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96: 804 – 10.en_US
dc.identifier.citedreferenceIrvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994; 106: 287 – 96.en_US
dc.identifier.citedreferencePallis AG, Mouzas IA, Vlachonikolis IG. The inflammatory bowel disease questionnaire: a review of its national validation studies. Inflamm Bowel Dis 2004; 10: 261 – 9.en_US
dc.identifier.citedreferenceJowett SL, Seal CJ, Phillips E, Gregory W, Barton JR, Welfare MR. Defining relapse of ulcerative colitis using a symptom-based activity index. Scand J Gastroenterol 2003; 38: 164 – 71.en_US
dc.identifier.citedreferenceVermeire S, Assche GV, Rutgeerts P. The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 580 – 6.en_US
dc.identifier.citedreferenceSolem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 707 – 12.en_US
dc.identifier.citedreferenceVermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 661 – 5.en_US
dc.identifier.citedreferenceKane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003; 98: 1309 – 14.en_US
dc.identifier.citedreferenceSugi K, Saitoh O, Hirata I, Katsu K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 1996; 91: 927 – 34.en_US
dc.identifier.citedreferenceSeo M, Okada M, Maeda K, Oh K. Correlation between endoscopic severity and the clinical activity index in ulcerative colitis. Am J Gastroenterol 1998; 93: 2124 – 9.en_US
dc.identifier.citedreferenceSeo M, Okada M, Yao T, Okabe N, Maeda K, Oh K. Evaluation of disease activity in patients with moderately active ulcerative colitis: comparisons between a new activity index and Truelove and Witts’ classification. Am J Gastroenterol 1995; 90: 1759 – 63.en_US
dc.identifier.citedreferenceSeo M, Okada M, Yao T, Matake H, Maeda K. Evaluation of the clinical course of acute attacks in patients with ulcerative colitis through the use of an activity index. J Gastroenterol 2002; 37: 29 – 34.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2036.2006.03205.x.pdf
Size:
643.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.